A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of PEGASYS plus ribavirin in male patients
with hemophilia A and chronic hepatitis C. All patients will receive PEGASYS 180 micrograms
s.c. weekly plus ribavirin 1000-1200mg p.o. daily (depending on body weight) for 48 weeks.
Following treatment there will be a 24 week period of treatment-free follow-up. The
anticipated time on study treatment is 3-12 months, and the target sample size is <100
individuals.